The quest for CJC-1295 in Aulla almost always leads to the same conclusion: research peptides are supplied via specialist online vendors, not local retail. This concentration of supply in online vendors is actually an advantage for quality — top vendors compete on lab-verified purity in ways brick-and-mortar outlets simply cannot. What reliably differentiates top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for safety screening. This guide guides Aulla researchers through that evaluation process and explains the signals that distinguish quality CJC-1295 suppliers.
Understanding CJC-1295 — Biology & Evidence
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Aulla researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
The most effective path to quality CJC-1295 is starting with community forums — peptide forums maintain informal vendor reputation databases that are more accurate than commercial vendor claims. Endotoxin testing in the COA is critical for any injectable research use — endotoxins from microbial contamination can trigger serious immune reactions even at minute levels. Signs of a credible vendor beyond COA quality: multi-year operating history, responsive technical support who understand testing methodology, and temperature-appropriate packaging with desiccant. Bacteriostatic water is the appropriate reconstitution medium for CJC-1295 — it contains 0.9% benzyl alcohol that inhibits bacterial growth and extends reconstituted shelf life to 4 weeks when kept refrigerated.
Order CJC-1295 — ships to Aulla
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means risk characterisation relies on animal studies, in-vitro work, and limited human observations — rather than the large-scale clinical data that informs approved drug safety. Proper handling of CJC-1295 requires careful sterile procedure — swabbed septum with alcohol prep pad, new needle for each draw, clean preparation area — and temperature control throughout the entire workflow. Verify the endotoxin level in your CJC-1295 batch COA before use in any in-vivo protocol — look for results expressed as EU/mg or EU/mL and verify they are within the acceptable range for your research context. The research literature on CJC-1295 should be reviewed carefully before designing any protocol — study designs, dosing ranges, and outcome measures vary significantly and not all findings translate directly.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
